Detected ·
Delix Therapeutics
$100MSeries C
Delix Therapeutics, a biotech developing psychedelic-inspired non-hallucinogenic depression treatments, raised $100M in an oversubscribed Series C co-led by Johnson & Johnson Innovation – JJDC and SV Health Investors’ Dementia Discovery Fund.
- Website
- —
- —
- Amount
- $100 000 000 USD
- Stage
- Series C
- Event
- Funding round
- Detected
- 2026-11-11 00:09:38 UTC
- Signal ID
- 59e7200c-d8e1-486f-a68f-017535cbec21
As the API returns it
{
"id": "59e7200c-d8e1-486f-a68f-017535cbec21",
"created_at": "2026-11-11T00:09:38.900730Z",
"company_name": "Delix Therapeutics",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 100000000,
"funding_currency": "USD",
"funding_stage": "series_c",
"message": "*Delix Therapeutics, a biotech developing psychedelic-inspired non-hallucinogenic depression treatments, raised $100M in an oversubscribed Series C co-led by Johnson & Johnson Innovation – JJDC and SV Health Investors’ Dementia Discovery Fund.*"
}